Viral respiratory tract infections in young children with cystic fibrosis: a prospective full-year seasonal study.
Coinfection
/ virology
Coronavirus Infections
/ complications
Cystic Fibrosis
/ complications
Female
France
Humans
Infant
Male
Picornaviridae Infections
/ complications
Prospective Studies
Respiratory Syncytial Virus Infections
/ complications
Respiratory Tract Infections
/ virology
Seasons
Severity of Illness Index
Viruses
/ genetics
Children
Cystic fibrosis
Respiratory virus
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
03 09 2019
03 09 2019
Historique:
received:
20
09
2018
accepted:
25
07
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
20
12
2019
Statut:
epublish
Résumé
Viral respiratory tract infections are common during early childhood. How they impact cystic fibrosis lung disease history in young children is poorly known. The principal aim of our study was to determinate respiratory tract infections frequency in this cystic fibrosis young population. Secondary outcomes were nature of viral agents recovered and impact of such infections. We conducted a prospective cohort study of 25 children affected by cystic fibrosis and aged less than 2 years. Nasal samplings were taken systematically monthly or bimonthly with additional samples taken during respiratory tract infections episodes. Ten pathogens were tested by a combination of five duplex RT-PCRs or PCRs: influenza A and B, respiratory syncytial virus (RSV), metapneumovirus (MPV), rhinovirus/enterovirus (RV/EV)), coronavirus (HKU1, NL63, 229E and OC43), parainfluenza virus (1-4), adenovirus and bocavirus (Respiratory Multi-Well System MWS r-gene®, BioMérieux, Marcy l'Étoile, France). Cycle thresholds (CTs) were reported for all positive samples and considered positive for values below 40. Quantitative variables were compared using a nonparametric statistical test (Wilcoxon signed rank for paired comparisons). Pearson's correlation coefficient (r) was used to assess relationships between two variables. Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA) or GraphPad Prism V6.00 (GraphPad Software, La Jolla, CA, USA). The significance level was set at 0.05. The mean age at inclusion was 9.6 ± 6.7 months. The patients had 3.4 ± 1.7 respiratory tract infections episodes per child per year. Forty-four respiratory tract infections (69%) were associated with virus: rhinovirus and enterovirus (RV/EV) were implied in 61% of them and respiratory syncytial virus (RSV) in 14%. Only one patient required hospitalization for lower respiratory tract infections. 86% of the patients were treated by antibiotics for a mean of 13.8 ± 6.2 days. RSV infections (n = 6) were usually of mild severity. Respiratory tract infections in young children with cystic fibrosis were of mild severity, rarely requiring hospitalization. Unsurprisingly, RV/EV were the most frequent agents. RSV-related morbidity seems low in this population. This raises the question of the usefulness of RSV preventive medication in this young population.
Sections du résumé
BACKGROUND
Viral respiratory tract infections are common during early childhood. How they impact cystic fibrosis lung disease history in young children is poorly known. The principal aim of our study was to determinate respiratory tract infections frequency in this cystic fibrosis young population. Secondary outcomes were nature of viral agents recovered and impact of such infections.
METHODS
We conducted a prospective cohort study of 25 children affected by cystic fibrosis and aged less than 2 years. Nasal samplings were taken systematically monthly or bimonthly with additional samples taken during respiratory tract infections episodes. Ten pathogens were tested by a combination of five duplex RT-PCRs or PCRs: influenza A and B, respiratory syncytial virus (RSV), metapneumovirus (MPV), rhinovirus/enterovirus (RV/EV)), coronavirus (HKU1, NL63, 229E and OC43), parainfluenza virus (1-4), adenovirus and bocavirus (Respiratory Multi-Well System MWS r-gene®, BioMérieux, Marcy l'Étoile, France). Cycle thresholds (CTs) were reported for all positive samples and considered positive for values below 40. Quantitative variables were compared using a nonparametric statistical test (Wilcoxon signed rank for paired comparisons). Pearson's correlation coefficient (r) was used to assess relationships between two variables. Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA) or GraphPad Prism V6.00 (GraphPad Software, La Jolla, CA, USA). The significance level was set at 0.05.
RESULTS
The mean age at inclusion was 9.6 ± 6.7 months. The patients had 3.4 ± 1.7 respiratory tract infections episodes per child per year. Forty-four respiratory tract infections (69%) were associated with virus: rhinovirus and enterovirus (RV/EV) were implied in 61% of them and respiratory syncytial virus (RSV) in 14%. Only one patient required hospitalization for lower respiratory tract infections. 86% of the patients were treated by antibiotics for a mean of 13.8 ± 6.2 days. RSV infections (n = 6) were usually of mild severity.
CONCLUSIONS
Respiratory tract infections in young children with cystic fibrosis were of mild severity, rarely requiring hospitalization. Unsurprisingly, RV/EV were the most frequent agents. RSV-related morbidity seems low in this population. This raises the question of the usefulness of RSV preventive medication in this young population.
Identifiants
pubmed: 31481063
doi: 10.1186/s12985-019-1208-7
pii: 10.1186/s12985-019-1208-7
pmc: PMC6724274
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111Références
Thorax. 1996 Nov;51(11):1115-22
pubmed: 8958895
J Cyst Fibros. 2014 Jan;13(1):49-55
pubmed: 23891398
Eur J Pediatr. 2017 Jul;176(7):891-897
pubmed: 28508992
Thorax. 2018 Jan;73(1):13-20
pubmed: 28778921
J Cyst Fibros. 2012 Sep;11(5):433-9
pubmed: 22579414
J Clin Virol. 2014 Jun;60(2):147-53
pubmed: 24637203
Pediatr Pulmonol. 1998 Dec;26(6):371-9
pubmed: 9888211
Eur Respir J. 2012 Feb;39(2):297-304
pubmed: 21719483
Pediatr Infect Dis J. 2015 Aug;34(8):907-9
pubmed: 26020408
Pediatr Infect Dis J. 2017 Jun;36(6):545-548
pubmed: 28005688
Influenza Other Respir Viruses. 2016 Mar;10(2):109-12
pubmed: 26493783
BMC Infect Dis. 2017 Jun 9;17(1):411
pubmed: 28599639
Eur J Microbiol Immunol (Bp). 2012 Sep;2(3):161-75
pubmed: 24688762
J Cyst Fibros. 2014 Dec;13(6):661-6
pubmed: 24637444
Pediatrics. 2008 Dec;122(6):1171-6
pubmed: 19047230
Chest. 2013 Mar;143(3):782-790
pubmed: 23188200
Influenza Other Respir Viruses. 2012 May;6(3):218-23
pubmed: 21955319
Pediatr Infect Dis J. 2016 Apr;35(4):379-83
pubmed: 26658528
Pediatrics. 2014 Aug;134(2):e620-38
pubmed: 25070304
Clin Infect Dis. 2017 Jun 15;64(12):1760-1767
pubmed: 28329304
Clin Microbiol Infect. 2013 Nov;19(11):E483-9
pubmed: 23795938
Scand J Infect Dis. 2013 Jan;45(1):65-9
pubmed: 22992129
Am J Dis Child. 1989 Jun;143(6):662-8
pubmed: 2543212
Pediatrics. 1999 Mar;103(3):619-26
pubmed: 10049966
J Clin Virol. 2017 Jan;86:1-4
pubmed: 27886635
Eur Respir J. 2012 Aug;40(2):510-2
pubmed: 22855475
J Pediatric Infect Dis Soc. 2013 Dec;2(4):345-51
pubmed: 24363931
Pediatr Pulmonol. 2014 Sep;49(9):926-31
pubmed: 24167159
Thorax. 2014 Mar;69(3):247-53
pubmed: 24127019
J Pediatr. 1988 Nov;113(5):826-30
pubmed: 3183835
J Clin Microbiol. 2013 Nov;51(11):3893-6
pubmed: 23966488